|
| Thursday, January 23, 2020 |
|
|
Eisai: Approval of Antiepileptic Drug Fycompa in Japan for Monotherapy and Pediatric Indications for Partial-Onset Seizures, as well as a New Formulation |
| The approval for monotherapy for partial-onset seizures is based on the results of a Phase III clinical study (FREEDOM/Study 342) conducted in Japan and South Korea. more info >> |
|
| Monday, January 20, 2020 |
|
|
Eisai Rated "A", the Highest Rating in the CDP Climate Change Report 2019 |
| Eisai Co., Ltd. has announced that it has been selected as the highest-rated company "A" in the Climate Change Report 2019 issued by the CDP, a non-profit organization, as a company that has performed particularly well in response to climate change. more info >> |
|
| Monday, January 6, 2020 |
|
|
Eisai's Fycompa for Adjunctive Treatment of Partial Onset Seizures Launched in China |
| Eisai Co., Ltd. has launched the in-house discovered and developed antiepileptic drug (AED) Fycompa, (generic name perampanel) for use in the adjunctive treatment of partial-onset seizures (with or without secondarily generalized seizures) in epilepsy patients 12 years of age and older. more info >> |
|
| Tuesday, December 24, 2019 |
|
|
Gilead and Eisai Enter Into Agreement in Japan for the Co-Promotion of the Investigational Rheumatoid Arthritis Therapy Filgotinib, Pending Regulatory Approval |
| Through this collaboration, Gilead Japan will retain responsibility for manufacturing and marketing approval of filgotinib, while Eisai will be responsible for product distribution in Japan in RA and other potential future indications. more info >> |
|
| Monday, December 23, 2019 |
|
|
U.S. FDA Approves Eisai's Dayvigo (Lemborexant) for Treatment of Insomnia in Adult Patients |
| Eisai Co., Ltd. has announced that the U.S. Food and Drug Administration (FDA) approved the new drug application for its in-house discovered and developed orexin receptor antagonist DAYVIGOTM (lemborexant). more info >> |
|
| Tuesday, December 10, 2019 |
|
|
Commencement of Major Renovation of Tsukuba Research Laboratories as Eisai Global Drug Discovery Center Aiming for Connecting Human and Human, and Data, and the World |
| Eisai Co., Ltd. announced today that Eisai had a groundbreaking ceremony for a major renovation of its Tsukuba Research Laboratories (Ibaraki, Japan) as part of strategic investment to realize Eisai's medium-term business plan "EWAY2025." more info >> |
|
| Monday, December 9, 2019 |
|
|
Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer's Disease Using Blood |
| Sysmex Corporation and Eisai Co., Ltd. are pursuing a joint project to develop a method of diagnosing Alzheimer's disease (AD) using blood, presented two posters showing the most recent data from the project. more info >> |
|
|
Eisai Satisfies All-Case Surveillance Condition for Approval of Anti-Cancer Agent Lenvima in Treatment of Thyroid Cancer |
| Eisai Co., Ltd. has received a notification from Japan's Ministry of Health, Labour, and Welfare (MHLW) to the effect that the "all-case surveillance" special drug use-results survey condition required for approval of the orally available kinase inhibitor LENVIMA (lenvatinib) in treatment of thyroid cancer has been cleared. more info >> |
|
| Thursday, December 5, 2019 |
|
|
Eisai to Present New Research on Eribulin (Halaven) at 42nd Annual San Antonio Breast Cancer Symposium |
| The symposium will be held from December 10 through 14, 2019, in San Antonio, Texas in the United States. more info >> |
|
| Monday, December 2, 2019 |
|
|
Eisai to Present Latest Data on Alzheimer's Disease / Dementia Pipeline at 12th Clinical Trials on Alzheimer's Disease Conference |
| BAN2401 is being jointly developed by Eisai and Biogen Inc. In addition, the simple blood diagnostics for AD are being jointly developing by Eisai and Sysmex Corporation. more info >> |
|
|
|
